An Open-Label, Multi-Center, Phase 2 Dose Ranging Study of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Be at least 18 years of age;

• Provide written informed consent;

• Patients with NK Stage 2 (PED) or Stage 3 (corneal ulcer);

Locations
United States
North Carolina
Wilmington Eye
RECRUITING
Leland
Time Frame
Start Date: 2024-07-31
Estimated Completion Date: 2025-11-30
Participants
Target number of participants: 12
Treatments
Active_comparator: BRM424 Ophthalmic Solution - Dose1
Active_comparator: BRM424 Ophthalmic Solution - Dose2
Related Therapeutic Areas
Neurotrophic Keratitis
Interstitial Keratitis
Sponsors
Leads: BRIM Biotechnology Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase 1/2, Multicenter, Double-Masked, Placebo-Controlled Study of KB801 in Subjects With Stage 2 or 3 Neurotrophic Keratitis

A Phase 1/2, Multicenter, Double-Masked, Placebo-Controlled Study of KB801 in Subjects With Stage 2 or 3 Neurotrophic Keratitis

Enrollment Status: Recruiting
Publish Date: May 31, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

Enrollment Status: Recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Phase: Phase 2

A Phase 4 Pilot Study With Extension to Assess the Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease and the Effect on Corneal Nerves and Neuropathic Corneal Pain

A Phase 4 Pilot Study With Extension to Assess the Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease and the Effect on Corneal Nerves and Neuropathic Corneal Pain

Enrollment Status: Recruiting
Publish Date: May 11, 2025
Intervention Type: Drug
Study Phase: Phase 4
View All